Opinion|Videos|July 8, 2024
Sequencing Considerations with CDK4/6 Inhibitors Used in Earlier Treatment
A panel of experts discuss sequencing considerations with CDK4/6.
Advertisement
Video content above is prompted by the following:
- How does incorporating CDK4/6i earlier in treatment impact how the relapsed/refractory setting is managed?
- Please include a discussion of ribociclib’s
MAINTAIN trial. Discuss your thoughts on continued use of CDK4/6i in the R/R setting, as well as sequencing considerations. - Please also include a discussion of capivasertib as a newly approved option based on the
CAPItello-291 trial.
- Please include a discussion of ribociclib’s
- (Dr. O’Shaughnessy) What are the primary differences in the toxicity profiles of abemaciclib and ribociclib when used in the adjuvant setting, and how are these prioritized when selecting a CDK4/6 inhibitor?
- Please include a discussion of the recent publication of long-term patient-reported outcomes with adjuvant abemaciclib
Advertisement
Related to this article
Legal and clinical experts examined the US medical aid in dying framework, its limits, and ethical debates.
Myeloma faculty from UT Southwestern Medical Center and pharmacy leaders from Texas Oncology discussed how teclistamab- and talquetamab-based regimens are reshaping early relapse in multiple myeloma. Observation-stay economics and physician comfort, not clinical data, are slowing delivery closer to home.
Speakers at IDWeek 2026 urged shifting global health partnerships from donor-recipient models to shared, locally led ownership as funding contracts.
Off-the-shelf CTX110 allogeneic CD19 CAR T shows responses in relapsed/refractory B-cell lymphoma, with manageable cytokine release syndrome.
Declining serum GFAP during MS treatment was tied to lower PIRA risk, supporting its use as a biomarker for treatment response.
David G. Mitchell, PharmD, MBA, CSP, FCPhA, of UC Davis Health, explains how AI-assisted prior authorizations have reduced denials and staff time without replacing pharmacist judgment.
Nearly half of working-age adults were inadequately insured in 2026, and half went without needed care due to cost, a Commonwealth Fund survey found.
Cross-ancestry GWAS of more than 1.8 million people flags SERPINA1, SMAD3, and other bronchiectasis targets shared with COPD and chronic bronchitis.
Advertisement
Advertisement
Trending on AJMC
1
Bepirovirsen Approval Offers New Option for Chronic HBV Treatment
2
Extension Studies in TPIP Show Promise in PAH, PH-ILD
3
Inhaled Amikacin Raises Culture Conversion in New MAC Lung Disease
4
Bronchiectasis GWAS Highlights Candidate Targets Shared With COPD
5